IP Verse

Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells - EP3377103B1

PatentPatent Analysis

EP3377103

REVITOPE
Application Number
EP16867215A
Filing Date
Nov 18, 2016
Status
Granted And Under Opposition
Feb 12, 2021
Grant Date
Mar 17, 2021
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3377103B1 was granted to Revitope on Mar 17, 2021 following the initial filing on Nov 18, 2016 under the application number EP16867215A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

TAKEDA PHARMACEUTICALDec 17, 2021WITHDRAWN
CHERRY BIOLABSDec 16, 2021WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents